Division of Research, Department of Surgery and the Genomic Sciences and Precision Medicine Center (GSPMC), Medical College of Wisconsin, Milwaukee, WI, USA.
Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 163 Avenue de Luminy, 13288, Marseille, France.
Nat Commun. 2019 Aug 28;10(1):3875. doi: 10.1038/s41467-019-11812-7.
Genetic studies have advanced our understanding of pancreatic cancer at a mechanistic and translational level. Genetic concepts and tools are increasingly starting to be applied to clinical practice, in particular for precision medicine efforts. However, epigenomics is rapidly emerging as a promising conceptual and methodological paradigm for advancing the knowledge of this disease. More importantly, recent studies have uncovered potentially actionable pathways, which support the prediction that future trials for pancreatic cancer will involve the vigorous testing of epigenomic therapeutics. Thus, epigenomics promises to generate a significant amount of new knowledge of both biological and medical importance.
遗传研究在机制和转化水平上推动了我们对胰腺癌的认识。遗传概念和工具越来越开始应用于临床实践，特别是在精准医学方面。然而，表观基因组学正在迅速成为推进该疾病知识的有前途的概念和方法学范例。更重要的是，最近的研究揭示了潜在的可操作途径，这支持了未来针对胰腺癌的试验将涉及大力测试表观基因组疗法的预测。因此，表观基因组学有望产生大量具有生物学和医学重要性的新知识。
Zotero 插件